Health Care [ 6/12 ] | Biotechnology [ 32/74 ]
NASDAQ | Common Stock
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020.
The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.05 Increased by +37.50% | -0.06 Increased by +16.67% |
| May 9, 24 | -0.07 Increased by +12.50% | -0.04 Decreased by -75.00% |
| Feb 29, 24 | -0.06 Increased by +45.45% | -0.09 Increased by +33.33% |
| Nov 13, 23 | -0.06 Increased by +78.57% | -0.09 Increased by +33.33% |
| Aug 10, 23 | -0.08 Increased by +81.82% | -0.07 Decreased by -14.29% |
| May 11, 23 | -0.08 Increased by +83.33% | -0.20 Increased by +60.00% |
| Mar 14, 23 | -0.11 Increased by +79.63% | -0.15 Increased by +26.67% |
| Nov 14, 22 | -0.28 Increased by +42.86% | -0.49 Increased by +42.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.05 M Increased by +27.14% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.29 M Increased by +12.54% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -1.10 M Increased by +45.43% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -1.24 M Increased by +51.42% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.44 M Increased by +60.61% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -1.48 M Increased by +62.70% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -2.02 M Increased by +55.19% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -2.54 M Increased by +38.14% | Decreased by N/A% Decreased by N/A% |